Dr. Anthony Gulati witnessed the evolution of oncology by watching his father practice medicine. After seeing the advances in the field and the great relationships his father developed with his patients, Dr. Gulati chose to practice oncology as well.
Dr. Gulati believes in a personal touch with his patients, striving to develop open communication and always remain accessible. He enjoys working with his patients to solve difficult treatment problems and offers personalized care to fit his patients’ needs.
After receiving his specialized fellowship training at Columbia University, Dr. Gulati chose to focus on treating patients with genitourinary, gastrointestinal and neuroendocrine cancers. In 2015, Dr. Gulati was awarded the Rookie of the Year award in the Department of Medicine at Stamford Health for quality patient care during his first year of service.
Dr. Gulati helps shape the future of oncology through clinical research and by serving as a clinical professor of medicine at Columbia University. He uses the latest treatments, including immunotherapy and clinical trials, to help his patients fight cancer.
Zacharia BE, Gulati AP, Bruce JN, Carminucci AS, Wardlaw SL, Siegelin M, Remotti H, Lignelli A, Fine RL. High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery. 2014 Apr;74(4):E447-55; discussion E455. doi: 10.1227/NEU.0000000000000251.
Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA, Mowatt KB, Dinnen RD, Mao Y, Stevens PD, Schrope B, Allendorf J, Lee JA, Sherman WH, Chabot JA. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother. Pharmacol. 2013 Mar;71(3):663-70. doi: 10.1007/s00280-012-2055-z. Epub 2013 Jan 31.
Gulati AP, Krantz B, Moss RA, Moyal WN, Tsushima DA, Mowatt KB, Schreibman S, Fine RL. Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature. Oncology. 2013;84(3):127-34. doi: 10.1159/000342961. Epub 2012 Dec 8.
Gulati AP, Saif MW. Is there a role for liver transplantation in metastatic pancreatic neuroendocrine tumors (PNET)? JOP. 2012 May 10;13(3):320-1.
Gulati AP, Saif MW. Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being treated for gastrointestinal stromal tumor (GIST). Anticancer Res. 2012 Apr;32(4):1375-7.
Gulati AP, Domchek SM. The clinical management of BRCA1 and BRCA2 mutation carriers. Curr. Oncol. Rep. 2008 Jan;10(1):47-53.
Gulati AP, Yang YM, Harter D, Mukhopadhyay A, Aggarwal BB, Benzil DL, Whysner J, Albino AP, Murali R, Jhanwar-Uniyal M.
Mol Carcinog. Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-kappaB, but not c-Jun N-terminal kinase and activated protein-1.
2006 Jan;45(1):26-37. Erratum in: Mol Carcinog. 2006. Jul;45(7):549.